St. Jude Medical announced that its Protégé spinal cord stimulator has received pre-market approval from the U.S. Food and Drug Administration, according to a NASDAQ report.
The Protégé spinal cord stimulator is intended for alleviating chronic pain and is the first neurostimulation system that can be upgraded without the need of a surgical replacement of the device. It provides access to therapies, stimulation modes, diagnostics and other features through software upgrades, according to the report.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws